文献詳細
特集 前立腺肥大症(BPH)薬物治療のニューノーマル―“とりあえず”ではなくベストな処方を目指して
〈併用療法〉
文献概要
▶ポイント
・α1遮断薬投与後に残存する過活動膀胱(OAB)症状は抗コリン薬やβ3作動薬の追加投与で改善する.
・有害事象の重症度や発現頻度は許容できるが,個別の丁寧な対応が必要である.
・追加薬剤の有効性,有害事象に関する直接比較による知見は乏しい.
・α1遮断薬投与後に残存する過活動膀胱(OAB)症状は抗コリン薬やβ3作動薬の追加投与で改善する.
・有害事象の重症度や発現頻度は許容できるが,個別の丁寧な対応が必要である.
・追加薬剤の有効性,有害事象に関する直接比較による知見は乏しい.
参考文献
1) Abrams P, et al : Safety and Tolerability of Tolterodine for the Treatment of Overactive Bladder in Men with Bladder Outlet Obstruction. J Urol 175 : 999-1004, 2006
2) Lee JY, et al : Comparison of Doxazosin with or without Tolterodine in Men with Symptomatic Bladder Outlet Obstruction and an Overactive Bladder. BJU Int 94 : 817-820, 2004
3) Yi QT, et al : Epidemic Investigation of Benign Prostatic Obstruction with Coexisting Overactive Bladder in Shanghai Pudong New Area and Its Impact on the Health-Related Quality of Life. BMC Urol 19 : 82, 2019
4) 日本泌尿器科学会 (編) : 男性下部尿路症状・前立腺肥大症診療ガイドライン. p2, リッチヒルメディカル, 東京, 2017
5) 日本老年医学会 (編) : 高齢者の安全な薬物治療ガイドライン2015. p120, メジカルビュー社, 東京, 2015
6) Yamaguchi O, et al : Solifenacin as Add-on Therapy for Overactive Bladder Symptom in Men Treated for Lower Urinary Tract Symptoms ― ASSIST, Randomized Controlled Study. Urology 78 : 126-133, 2011
7) Nishizawa O, et al : Randomized Controlled Trial to Treat Benign Prostatic Hyperplasia with Overactive Bladder Using an Alpha-Blocker Combined with Anticholinergics. LUTS 3 : 29-35, 2011
8) Takeda M, et al : Clinical Efficacy and Safety of Imidafenacin as Add-on Treatment for Persistent Overactive Bladder Symptoms Despite α-blocker Treatment in Patients with BPH : The ADDITION Study. Urology 82 : 887-893, 2013
9) Kim TH, et al : Comparison of the Efficacy and Safety of Tolterodine 2 mg and 4 mg Combined with an α-blocker in Men with Lower Urinary Tract Symptoms (LUTS) and Overactive Bladder : A Randomized Control Trial. BJU Int 117 : 307-315, 2016
10) Matsukawa Y, et al : Comparison in the Efficacy of Fesoterodine or Mirabegron Add-on Therapy to Silodosin for Patients with Benign Prostatic Hyperplasia Complicated by Overactive Bladder : A Randomized, Prospective Trial Using Urodynamic Studies. Neurourol Urodyn 38 : 941-949, 2019
11) Kakizaki H, et al : Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms : A Randomized, Placebo-Controlled Study (MATCH). Eur Urol Focus 6 : 729-737, 2020
12) Ishikawa K, et al : Efficacy and Safety of Vibegron Add-on Therapy in Men with Persistent Storage Symptoms After Receiving Alpha 1-blocker or Phosphodiesterase 5 Inhibitor : A Preliminary Study. Urology 2021 [Online ahead of print]
13) Pazan F, et al : The JAPAN-FORTA (Fit fOR The Aged) List : Consensus Validation of a Clinical Tool to Improve Drug Therapy in Older Adults. Arch Gerontol Geriatr 91 : 104217, 2020
掲載誌情報